medicaid and glp 1 coverage The evolving landscape of anti-obesity medication in Medicaid Coverage of and Spending

Strengths Acts via multiple pathways (GLP-1, AMPK, microbiome) Has existing human data showing reductions in fasting glucose, HbA1c, lipids Support receptor expression and islet health Limitations Low absorption and bioavailability Gastrointestinal discomfort is common (diarrhea, cramping)

Note: Anti-Obesity GLP-1s Wegovy and Zepbound, Anti-Diabetes GLP-1s Ozempic and Mounjaro Source: IQVIA MAAS Patient Behavior Library Tool

Take back control, quiet cravings, and hush your hunger

Fitty GLP-1 Daily & ACV Fizz: Cravings Control Solution

Ive been taking ultimate weight control for a few months now and have really seen the difference

When patients on GLP-1 therapy also make healthy lifestyle choicesgetting enough sleep and exercising, for examplethe benefits are significantly greater.